Additionally, because the evidence indicates there are no signs of worsening cognition or new onset diabetes, PCSK9 inhibitors may be a good option for patients who are particularly concerned about these ADEs with long-term statin use. This evidence concerns the gene PCSK9 and diabetes mellitus.